Epidemiology of metabolic syndrome in Europe

September 05, 2005

Previously, several different definitions for the metabolic syndrome (MetS) had been proposed and used by researchers. This resulted in confusion about the frequency of the MetS and its relationship with mortality. Recently, the Consensus Panel International Diabetes Federation (IDF) proposed a new definition for the MetS in order to overcome the problems of comparability. The new IDF definition issued in April 2005, see also: (http://www.idf.org/webdata/docs/Metabolic_syndrome_definition.pdf). This IDF definition emphasizes the importance of central obesity (defined as waist circumference „d 94cm for Europid men and „d 80 cm for Europid women, with ethnic specific values for other groups).

A person can be defined as having the MetS if he/she has central obesity plus any two of the following four factors:

1) serum triglycerides greater than or equal to 1.7 mmol/L, or specific treatment for this lipid abnormality;
2) serum HDL-cholesterol < 1.03 mmol/L in males and < 1.29 mmol/L in females, or specific treatment for this lipid abnormality
3) blood pressure greater than or equal to 130 mmHg systolic or „d85 mmHg diastolic, or treatment of previously diagnosed hypertension;
4) fasting plasma glucose greater than or equal to 5.6 mmol/L, or previously diagnosed type 2 diabetes.

Using the data from 4600 men and 5500 women aged 30-89 years from seven European population-based studies were included in a collaborative analysis to study the epidemiology of the MetS. In subjects with the MetS, 91% of men and 90% of women had hypertension; the proportions for hyperglycemia were 73% and 64%; for elevated triglyceride and/or low-HDL 77% and 77%, respectively. The overall prevalence of the MetS was 38% in men and 36% in women. The age-specific prevalence increased up to the age of 60 years and leveled off thereafter in men, while in women it increased up to the oldest age group.

Table. The prevalence of the metabolic syndrome (%) in European men and women.

In the prospective follow-up with a median of 8.9 years cardiovascular (CVD) mortality was increased by 45% in men with MetS and by 73% in women with MetS compared with men and women without MetS. The analyses were adjusted for age, cholesterol and smoking. The corresponding relative risks (RRs) of MetS for all-cause mortality were 27% in men and 25% in women. In general, the 2005 IDF definition of MetS will produce a somewhat higher prevalence in Europe than previous definitions of the MetS did. Compared with men without the MetS, men with the MetS had increased CVD mortality regardless of the presence of diabetes. In women, however, the MetS was only predictive of CVD when diabetic women were included in the analysis. This confirms the finding from several previous studies that women with diabetes have a particularly risk of CVD.
-end-


European Society of Cardiology

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.